Activity by briankilen
Mayo Clinic and Mandarin Oriental, Bodrum will introduce a new program reflecting a joint commitment to wellness, the Mayo Clinic Healthy Living Programme at Mandarin Oriental, Bodrum will combine the research-based medical expertise of Mayo Clinic with Mandarin Orientalâ€™s signature treatments and therapies, offered in its award-winning, expansive Spa. This collaboration is the first of its kind for the clinic.
Launching in January 2016 with a focus on preventive wellness and designed to inspire a more balanced lifestyle, the wellness program will offer guests a choice of tailor-made experiences from one day assessments to five day retreats, as well as a la carte services. [...]
Alaska Native people have twice the rates of colorectal cancer as rest of U.S.
ROCHESTER, Minn. â€” Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of worldâ€™s highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic.
The remote residence of many Alaska Native people in sparsely distributed communities across vast roadless regions creates a barrier to screening with conventional tools, such as a colonoscopy. Stool DNA testing, which was recently approved by the U.S. Food and Drug Administration (FDA), may offer a workable and effective screening method for this population. The research was published in the journal Mayo Clinic Proceedings and funded by a competitive grant from the Richard M. Schulze Family Foundation.
The stool DNA test is a noninvasive screening tool that identifies characteristic chemical changes in stool that signal the presence of cancer or precancerous polyps. The test, which requires no bowel preparation and no diet or medication restrictions, can be done from home via a mailed sampling kit.
â€śStool DNA detects colorectal cancer and highest risk precancerous polyps with high accuracy, and its application within a screening program could translate into more effective prevention and control of the leading cancer among Alaska Native people,â€ť says David Ahlquist, M.D., a study author and co-inventor of the stool DNA test.
ROCHESTER, Minn. â€” Colorectal cancer remains the second leading cause of cancer death for men and women combined in the U.S. The goal of screening is to reduce the number of people who die from this common cancer. According to Mayo Clinic cancer experts there are gaps in current screening approaches in terms of detection accuracy, patient willingness to use them, and accessibility.
Recently, the U.S. Preventive Services Task Force (USPSTF) announced draft recommendations on colorectal cancer screening. The task force recommended screening for colorectal cancer using the conventional tools, including, fecal occult blood testing, sigmoidoscopy or colonoscopy in adults, beginning at age 50 years and continuing until age 75.
The task force concluded that the evidence is less mature to support use of the stool DNA test as a screening modality for colorectal cancer and designated this new test as an alternative rather than front-line screening approach.Â The innovative and noninvasive stool DNA test (Cologuard) was co-developed by Mayo Clinic and Exact Sciences scientists to improve screening accuracy, encourage participation with its user-friendly features, and remove access barriers. The stool DNA test has met the stringent reviews and been approved by both the US Food & Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS). Mayo Clinic strongly urges the USPSTF to unambiguously support the stool DNA as a fully legitimate colorectal cancer screening option.
â€śThere is compelling scientific evidence that this innovative approach can increase screening accuracy and potentially save lives,â€ť says John Noseworthy, M.D., President and CEO, Mayo Clinic.Â "We need to remove cost, cultural, locationÂ and other barriers to improve access toÂ effective screening.â€ť
Each company receives a $50,000 award and one year of consultation
ROCHESTER, Minn. â€“ On Oct. 1, Care at Hand and Wellpepper were selected as winners of the first-ever Mayo Clinic Think Big Challenge, which was sponsored by Mayo Clinic Center for Innovation (CFI), Mayo Clinic Ventures and AVIA Health Innovation. Winners will receive a $50,000 award and one year of consultation to help develop their innovative concepts for market.
The winners were chosen by attendees at Transform 2015, an annual gathering of industry leaders exploring the future of health and health care, which is hosted by the CFI. More than 130 applicants across the nation submitted ideas for the inaugural competition, and six finalist companies were selected for the final round of judging.
Care at Hand of San Francisco and Rockville, Maryland, won the Got Health Award, which focuses on ideas to enable healthy people to stay healthy.
Led by a team spanning medicine to engineering, Care at Hand is recognized for its work on an evidence-based smart survey and analytics platform that predicts and prevents hospitalizations using nonmedical workers. Forbes underscored Care at Handâ€™s leadership and investment in digital health technologies, saying Care at Hand is â€śblazing trails in telehealth and poised to become [a] household name.â€ť
Wellpepper of Seattle won the I Am Not My Disease Award, which focuses on helping people with chronic illnesses live better lives. [...]
Vitesse formed to identify and advance early stage biologic research in immunology, hematology and oncology
Deerfield, IL., Rochester, MN and South San Francisco, CA. â€” Baxter Ventures, the venture arm of Baxter International Inc. (NYSE:BAX), Mayo Clinic and Velocity Pharmaceutical Development, LLC (â€śVPDâ€ť) today announced the formation of Vitesse Biologics, LLC, (â€śVitesseâ€ť). Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology. Following the spin-off of Baxter BioScience as Baxalta Incorporated, anticipated to take place by mid-2015, the Vitesse relationship will be managed by the planned venture arm, Baxalta Ventures, for the new company.
Baxter Media Contact:Â Kellie Hotz,Â (224) 948-5353, email@example.com
Baxter Investor Contact:Â Mary Kay Ladone, (224) 948-3371
Mayo Clinic Media Contact:Â Brian Kilen, (507) 284-5005, firstname.lastname@example.org
Velocity Media Contact:Â Leslie Loven, (415) 509-5110,Â Â email@example.com
Mayo Clinic Researcher Explains Five Individual Categories for Treatment of Obesity
ROCHESTER, Minn. â€“ Mayo Clinic researchers have identified five sub-categories of obesity in an effort to determine the most effective, individual treatments. More than two in three adults are considered to be overweight or obese and 17 percent of children are obese in the United States. Obesity is a costly health issue that increases the risk for heart disease, type 2 diabetes, and cancer, among others. The prevalence of obesity continues to rise despite education and efforts around diet, exercise, and drug/surgical therapy. In response, researchers asked how the gastrointestinal system affects obesity.
ROCHESTER, Minn. -- With Motherâ€™s Day being May 10Â and May being Womenâ€™s Health Month, Mayo Clinic offers expert guidance on fertility and conception.
Mayo Clinic expert Jani Jensen, M.D. is available to talk about the latest research and provide expert guidance for reporters writing articles on womenâ€™s health and fertility and conception.
She is co-author of the recently released Mayo Clinic Guide to Fertility and Conception. The comprehensive book provides answers and explanations for nearly every aspect of achieving a successful pregnancy. It covers lifestyle and nutrition, the intricacies of natural conception, common fertility problems, the latest medical treatments to help (including intrauterine insemination, in-vitro fertilization and donors), and information on special situations (fertility preservation, choosing single parenthood, same-sex couples and more). [...]
ROCHESTER, Minn.Â â€•Â Here are highlights from the AprilÂ issue ofÂ Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee.Â Mayo Clinic Health LetterÂ attribution is required. Include the following subscription information as your editorial policies permit: VisitÂ http://healthletter.mayoclinic.com/Â or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text: Mayo Clinic Health Letter April 2015Â (for journalists only).
Exercise eases depression symptoms
Increasing evidence shows that exercise can ease the symptoms of depression and anxiety. The April issue of Mayo Clinic Health Letter covers how exercise changes the brain and alleviates symptoms.
Depression is linked to abnormally low levels of certain neurotransmitters â€• chemicals in the brain that allow nerves to communicate with one another. Having less norepinephrine, dopamine and serotonin in the brain results in lower nerve stimulation than usual, contributing to feelings of sadness and emptiness, loss of interest in normal activities, tiredness, anxiety and trouble thinking.
Antidepressant medications work by increasing the levels of these chemicals and bringing them back to normal. Exercise does the same thing. In addition, new evidence shows that exercise sets into motion changes that protect the brain against the damaging effects of stress and enhance resilience to depression.
Exercise also has positive emotional and social effects that can help deal with stress and depression. Regular exercise helps:
ROCHESTER, Minn. â€“ Today Mayo Clinic announced two new applications for the Apple Watch that will help patients and providers manage schedules and visits. The Mayo Clinic app update is available on iTunes. The Synthesis app for providers is available to Mayo Clinic staff.
â€śIt is important that we interact with patients so that it seamlessly enhances their health care experiences. Whether this is through the Mayo Clinic app., remote monitoring, or the Apple watch, health consumer experience will continue to drive these technologies forward and Mayo Clinic will continue to lead with cutting edge technologies that benefit both our patients and
staff.â€ť says John T. Wald M.D., Medical Director, Mayo Clinic Public Affairs.
Journalists: Sound bites with Dr. Wald are available in the downloads.
MEDIA CONTACT: Brian Kilen, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org
AgreementÂ includes deployment of existing Optum360 revenue management services technology, development of new tools and delivery of services to increase patient satisfaction
Optum360 and Mayo Clinic announced today that they are collaborating to develop new revenue management services capabilities aimed at improving patient experiences and satisfaction while reducing administrative costs for health care providers.
Optum360 and Mayo Clinic will collaborate on enhancing and redesigning specific elements of the revenue cycle to increase efficiency while creating a convenient, accurate, transparent and personal experience for patients. A key focus is improving the interaction between the provider and payer by opening channels of communication early in the care process. The agreement includes a next-generation patient cost estimator, streamlining prior authorization/pre-certification, enhanced claims editing functions and administrative simplification of billing activities associated with pre-care packaged pricing.
â€śMayo Clinic and Optum360 have a shared vision of how a patient can best experience the revenueÂ cycle as part of their care,â€ť said Sandhya Pruthi, M.D., Mayo Clinic Medical Director for Patient Experience, Rochester. â€śThrough our work together, we will also address the unique needs and regulatory requirements of the market and deliver a superior patient experience.â€ť
MEDIA CONTACT: Brian Kilen, Mayo Clinic Public Affairs, 507-284-5005, email@example.com
ROCHESTER, Minn.Â â€•Â Here are highlights from theÂ March issue ofÂ Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee.Â Mayo Clinic Health LetterÂ attribution is required. Include the following subscription information as your editorial policies permit: VisitÂ http://healthletter.mayoclinic.com/ or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text:Â Mayo Clinic Health Letter March 2015Â (for journalists only).
Pain medications might not work well for chronic pain â€• pain that doesnâ€™t go away with time. The March issue of Mayo Clinic Health Letter covers other types of medications and strategies to consider as part of long-term pain management.
Deciding on potential drug therapy for chronic pain usually involves analysis of the cause or causes of pain and knowing which type of drugs may be beneficial. Pain medications typically work well for pain resulting from headache, an injury or surgery. These same medications can lose their effectiveness over time, and some may even make pain worse or cause unacceptable side effects. Other options include:
Albuquerque, NM â€” Mayo Clinic Health Solutions today announced a collaboration with Lovelace Health System to serve employers in the Albuquerque and Roswell area with self-funded plan options.Â â€śThe agreement combines the national proficiency and expertise of Mayo Clinic Health Solutions with excellence in local medical care at Lovelace Health System,â€ť says Greg Couser, M.D., Chief Medical Officer, Mayo Clinic Health Solutions.
Under this relationship, Mayo Clinic Health Solutions will offer third party administrative services for self-funded plans through brokers and consultants as well as local employers. Mayo Clinic Health Solutions offers a national network option to supplement the local provider network of the Lovelace Health System. Health plan administration services offered through Mayo Clinic Health Solutions for self-funded employer health plans will be available with effective dates beginning July 1, 2015.
For more information, visit Mayo Clinic Global Business Solutions. [...]
â€śWe are hoping that this technology will be game-changer. These patch biosensors may help us reduce global obesity and diabetes,â€ť says James Levine, M.D., Ph.D., a Mayo Clinic endocrinologist and obesity researcher. â€śThey are accurate, inexpensive, and can be integrated into the care people receive."
A first-of-its-kind, the wearable patch sensors are the size of a small bandage, and are designed to be painless, wireless and disposable. In the bandage is a sensor that communicates via a closed-loop diabetes management system which is compatible with cell phones. The system will allow researchers to monitor movement and develop treatments for obesity and related conditions.
MEDIA CONTACT: Brian Kilen, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org
ROCHESTER, Minn. â€” When people have health questions, many turn to the Internet, and Google in particular, as the first stop for finding health information. Now, when users ask Google about common health conditions, they will get relevant medical facts up front. For example, a search for arthritis will show, up front, a few basic facts about arthritis and a definition. To ensure quality and accuracy, teams of doctors including expert clinicians at Mayo Clinic have reviewed the facts, and have written succinct definitions for the conditions.
The goal of this new feature is to provide medical information in a digestible way and get basic answers quickly. Google will provide information about symptoms and treatments, and details about how common a condition is, whether itâ€™s critical, if itâ€™s contagious, what ages it affects, and more. It will also provide high-quality illustrations and a streamlined design that makes it easier to tap or click through to more in depth information on other sites.
MEDIA CONTACT: Brian Kilen, Mayo Clinic Public Affairs, 507-284-5005, email@example.com [...]
Unique Arrangement Aims to Build on the Success of CologuardÂ®
Exact Sciences Corp. (NASDAQ: EXAS) and Mayo Clinic today announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.
The amended agreement extends the collaboration for five more years with David Ahlquist, M.D., a Mayo Clinic gastroenterologist, and his lab at Mayo Clinic. Exact Sciences will continue to have rights to certain intellectual property, including patents, know-how and new markers.
The original June 11, 2009 agreement between Exact Sciences and Mayo Clinic led to the development of Cologuard, which the U.S. Food and Drug Administration (FDA) approved on August 11, 2014. Cologuard is the first and only FDA-approved stool DNA-based colorectal cancer screening test.
â€śThis unique collaboration is producing powerful results,â€ť said John Noseworthy, M.D., president and CEO of Mayo Clinic. â€śThe success of our teams in developing Cologuard exemplifies what can happen when two organizations combine their expertise and unite toward a single goal.â€ť
â€śBy expanding our relationship with Mayo Clinic, we have an opportunity to build on our shared successes and continue looking for new opportunities to take on some of the deadliest forms of cancer,â€ť said Kevin Conroy, CEO and chairman of Exact Sciences. â€śThis collaboration and our ability to leverage both institutionsâ€™ distinctly different strengths is unique in American industry. But our ambitions cannot end with Cologuard. We expect our collaboration to continue producing breakthroughs that can change patientsâ€™ lives.â€ť
J.P. Fielder,Â Exact Sciences Corp. Â (202) 746 6352 Â Jfielder@exactsciences.com
Brian Kilen, Mayo Clinic 507-284-5005 firstname.lastname@example.orgÂ Â Â Â Â Â Â
ROCHESTER, Minn. â€•Â Here are highlights from the January issue ofÂ Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee.Â Mayo Clinic Health LetterÂ attribution is required. Include the following subscription information as your editorial policies permit: VisitÂ http://healthletter.mayoclinic.com/ or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text:Â Mayo Clinic Health Letter January 2015Â (for journalists only).
Wrist fractures: Treatment decisions not always straightforward
The wrist is made up of eight small bones at the base of the hand and two in the forearm â€• the radius and ulna â€• that connect the elbow to the wrist bones. Any one of these bones can be fractured; a wrist fracture is a widely variable injury.
One of the primary decisions is the choice between nonsurgical and surgical treatment. Sometimes the choice is clear, and sometimes itâ€™s not. Factors to consider include overall health, lifestyle, ability to tolerate surgery and the desire for a fully functioning wrist. [...]
China collaboration with Hillhouse Capital strengthens Mayo Clinicâ€™s mission to improve health care worldwide
Today, Mayo Clinic announced it has entered into a joint venture agreement with Hillhouse Capital to advance the quality of health care in China. By combining Mayo Clinicâ€™s patient care, medical research and education with Hillhouseâ€™s China expertise and healthcare industry partnerships, the collaboration establishes a new company to improve health care delivery and efficiency in China.
â€śWe are excited to collaborate with Hillhouse to provide Mayo Clinic knowledge and guidance to improve the quality of health care to theÂ people of China,â€ť said Paul Limburg, M.D., Medical Director, Mayo Clinic Global Business Solutions. â€śOur collaboration with Hillhouse extends Mayo Clinicâ€™s reach and is at the core of Mayo Clinicâ€™s mission to inspire hope and healing to people everywhere.â€ť
The new venture benefits from recent policy changes by Chinese regulators to encourage private investment in health care. Mayo Clinic and Hillhouse believe that this collaboration presents a unique opportunity to leverage Mayo Clinicâ€™s valuable capabilities in medical technology and management and Hillhouseâ€™s strong in-country knowledge to deliver high-quality health care services to Chinese healthcare providers and patients. [...]
ROCHESTER, Minn. â€•Â Here are highlights from the December issue ofÂ Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee.Â Mayo Clinic Health LetterÂ attribution is required. Include the following subscription information as your editorial policies permit: VisitÂ http://healthletter.mayoclinic.com/ or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text:Â Mayo Clinic Health LetterÂ December 2014Â (for journalists only).
Myths and facts about how medications affect older adults
Older adults need to be especially vigilant about drug safety, according to the December issue of Mayo Clinic Health Letter. Thatâ€™s because older adults are more likely to be taking more than one medication at a time. Interactions between drugs can cause side effects that might not occur if a drug were taken alone. And, physical changes in older adults can alter both the effectiveness of a medication and side effects, compared with what a younger adult might experience. [...]
Mayo Clinic hosting immersion program for innovative medical startups accelerating advances in patient care
ROCHESTER, Minn., â€”Â Mayo Clinic announced today a new collaboration with Techstars to offer the Techstars++ program. The Techstars++ program will bring together health care entrepreneurs and companies with Mayo Clinic to find innovative solutions to improve patient care at an accelerated pace. Mayo Clinic is the first to participate in this new program.
Techstars is a mentorship-driven accelerator program with a track record of helping to develop businesses, especially technology startups. The Techstars++ program offers companies from the Techstars portfolio of 500 alumni companies the opportunity to extend their Techstars experience by spending time on-site and engaging deeply with a corporation/organization - Mayo Clinic in this initial program. [...]
John Burnett Jr., M.D., a Mayo Clinic cardiologist, has been selected as a winner of GSKâ€™s 2014 Discovery Fast Track Challenge, which is designed to accelerate the translation of academic research into novel therapies. Dr. Burnett will work with scientists in GSKâ€™s Discovery Partnerships with Academia (DPAc) and the Molecular Discovery Research teams to test their hypotheses and screen targets against GSKâ€™s compound collection.
Active compounds could then form the basis of full drug discovery programs that may ultimately lead to innovative medicines for anti-hypertensive agents.
Dr. Burnett submitted one of 14 winning proposals, chosen from 428 entries from 234 universities and academic institutes from across 26 countries. Research between Mayo Clinic and GSK will focus on treatments for resistant hypertension.
â€śWe see this as a huge need, clinically, and we think our screen could lead to a breakthrough drug for the treatment of resistant hypertension, which is growing worldwide,â€ť said Dr. Burnett. [...]